4D MOLECULAR THERAPEUTICS INC. - COMMON STOCK

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

08 2 2025 11:30:24 提供 Nasdaq GlobeNewswire

4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population

29 1 2025 05:00:00 提供 Nasdaq GlobeNewswire

4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path

10 1 2025 05:00:00 提供 Nasdaq GlobeNewswire

4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway

10 1 2025 05:00:00 提供 Nasdaq GlobeNewswire

4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS

16 12 2024 05:00:00 提供 Nasdaq GlobeNewswire

4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV

14 11 2024 05:00:00 提供 Nasdaq GlobeNewswire

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

13 11 2024 13:05:00 提供 Nasdaq GlobeNewswire

4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference

23 9 2024 05:00:00 提供 Nasdaq GlobeNewswire

4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day

18 9 2024 13:05:00 提供 Nasdaq GlobeNewswire

4DMT Announces Presentations at Upcoming Retina Conferences

05 9 2024 05:00:00 提供 Nasdaq GlobeNewswire

4DMT to Participate in the 2024 Cantor Global Healthcare Conference

03 9 2024 05:00:00 提供 Nasdaq GlobeNewswire

4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024

27 8 2024 05:00:00 提供 Nasdaq GlobeNewswire

4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

12 8 2024 05:00:00 提供 Nasdaq GlobeNewswire

4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights

08 8 2024 13:05:01 提供 Nasdaq GlobeNewswire

4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board

05 8 2024 05:00:00 提供 Nasdaq GlobeNewswire

4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity

17 7 2024 02:00:00 提供 Nasdaq GlobeNewswire

4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy

24 6 2024 05:00:00 提供 Nasdaq GlobeNewswire

4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast

18 6 2024 05:00:00 提供 Nasdaq GlobeNewswire

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

08 6 2024 13:30:00 提供 Nasdaq GlobeNewswire

4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference

06 6 2024 04:30:00 提供 Nasdaq GlobeNewswire